Detalhe da pesquisa
1.
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
Mov Disord
; 38(7): 1236-1252, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37147135
2.
Stalevo® : A pioneering treatment for OFF periods in Parkinsons disease.
Eur J Neurol
; 30 Suppl 2: 3-8, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37500177
3.
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
Eur J Neurol
; 30(5): 1465-1480, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36757008
4.
Non-motor features of Parkinson disease.
Nat Rev Neurosci
; 18(7): 435-450, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592904
5.
Non-motor features of Parkinson disease.
Nat Rev Neurosci
; 18(8): 509, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28720825
6.
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease.
Molecules
; 27(7)2022 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35408767
7.
Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers.
J Neural Transm (Vienna)
; 127(5): 707-714, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786692
8.
The 20th anniversary of the first clinical use of Stalevo®.
Eur J Neurol
; 30 Suppl 2: 1-2, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37489699
9.
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.
Phytother Res
; 32(4): 678-687, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29368409
10.
Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
Mov Disord
; 31(9): 1381-8, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27133947
11.
Dyskinesia Matters: But Not as Much as It Used to.
Mov Disord
; 35(5): 900-901, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415717
12.
Gerald Malcolm Stern b.1930 d.2018 : Neurologist and scientist.
J Neural Transm (Vienna)
; 127(5): 701-702, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32157407
13.
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.
J Neural Transm (Vienna)
; 122(6): 779-88, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25503828
14.
Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
Mov Disord
; 34(12): 1930-1931, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31845760
15.
Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
Mov Disord
; 34(6): 816-819, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30983023
16.
Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.
J Neural Transm (Vienna)
; 121(12): 1493-505, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24781752
17.
Adenosine A2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.
J Pharmacol Sci
; 124(4): 480-5, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24681641
18.
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected.
Pract Neurol
; 14(5): 310-22, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24699931
19.
Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra.
Eur J Neurosci
; 38(3): 2468-76, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23692556
20.
The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wave.
Mov Disord
; 33(11): 1670-1672, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30485909